Lensar Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Lensar Inc's ROI in the second quarter of 2026?
Lensar Inc achieved a return on average invested assets (ROI) of 75.31 % in its second quarter of 2026, this is above LNSR's average return on investment of -33.68%.
Lensar Inc invested over the 12 months ending in its second quarter of 2026 $44 million

Despite the deterioration in its net income, company has improved ROI compared to the first quarter of 2026.

Within the Healthcare sector 6 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 44, from total ROI ranking in the first quarter of 2026 at 894.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-6.84 %	-16.7 %	-21.93 %	-20.06 %	-16.38 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	50	48	42	34	40
Return On Investment (TTM)	75.31 %	71.13 %	-84.29 %	-119.91 %	-105.06 %
LNSR's Overall Ranking	# 44	# 894	# 3592	# 3298	#
Seq. Investment Change TTM	5.8 %	1.62 %	-5.36 %	-8.45 %	-5.4 %
Seq. Net Income Change TTM	12.01 %	-	-	-	-
Net Income (TTM) in Millions	33	29	-34	-52	-49

LNSR Company Profile >> Back to LNSR Roi Comparisons >> See Annual LNSR Return On Investment

Return On Investment LNSR's Ranking
Within:	No.
Industry	# 1
Sector	# 7
Overall	# 44

Return On Investment Statistics
High	Average	Low
107.45 %	-33.68 %	-124.27 %
(Jun 30 2026)		(Dec 31 2025)

News about Lensar Inc Return on Investment ROI

LENSAR Celebrates Milestone One Million Cataract Procedures Completed with Advanced Laser Technology

October 8, 2024

In a remarkable achievement for both LENSAR, Inc. and the field of ophthalmology, the medical technology company announced recently that it has surpassed a significant milestone: the completion of one million cataract procedures utilizing its state-of-the-art LENSAR Cataract Laser System. This achievement is not just a statistic, but a reflection of the company s commitment to innovation, patient care, and enhancing surgical outcomes in the treatment of cataracts. The Evolution of Cataract SurgeryCataract surgery has long been one of the most commonly performed surgical procedures worldwide, traditionally relying on manual techniques and technology that have seen gradual improvements over the decades. The advent of advanced laser-assisted technology has ushered in a new era in this field, providing both surgeons and patients with enhanced precision, efficiency, and outcomes.

LENSAR’s Strategic Moves Amid Financial Headwinds: A Focus on Innovation and Growth in Cataract Treatment

October 1, 2024

Article Outline:1. Introduction - Overview of LENSAR, Inc. a medical technology company specializing in cataract treatment. - Mention recent stock options inducement to key personnel and financial performance.2. Recent Developments - Inducement Grants: On October 1, 2024, LENSAR s board granted stock options for 875 shares to two non-executive employees. - Compliance with Nasdaq Listing Rule 5635(c)(4): This regulation allows companies to grant inducement options as part of a recruitment strategy.

Financial Statements
Lensar Inc's II. Quarter Investments	$ 50 Millions	LNSR's Balance sheet
Lensar Inc's II. Quarter Income	$ 2 Millions	Quarterly LNSR's Income Statement
LNSR's Income by Division		See LNSR's Income by Division

LNSR Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	30	-10	51	58	44
Y / Y Investment Growth	-	-	-11.49 %	30.46 %	-23.08 %
Net Income in Millions	-34	-31	-14	-20	-20
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-115.91 %	-	-28.04 %	-34.36 %	-44.12 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LNSR's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LNSR's Competitors
Subscribers only: Roi for Lensar Inc's Suppliers
Subscribers only: Return On Investment for LNSR's Customers

Other Ratios
LNSR's Roa	LNSR's Inventory Turnover Ratio	LNSR's Growth Rates	LNSR's Dividend Statistics
	LNSR's Profitability Ratios	LNSR's Asset Turnover Ratio	LNSR's Dividend Growth
LNSR's Roe	LNSR's Valuation Ratios	LNSR's Financial Strength Ratios	LNSR's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector	ROI
Omeros Corporation	198.34 %
Elutia Inc	191.75 %
Sanuwave Health Inc	167.92 %
Vor Biopharma Inc	162.71 %
Capforce Inc	161.42 %
Kyntra Bio Inc	157.74 %
Silexion Therapeutics Corp	127.60 %
Quince Therapeutics Inc	112.49 %
Pulmatrix Inc	108.83 %
Interpace Biosciences Inc	100.71 %
Rigel Pharmaceuticals Inc	89.00 %
Oncotelic Therapeutics Inc	87.35 %
Arbutus Biopharma Corp	85.89 %
Actinium Pharmaceuticals Inc	84.38 %
Exelixis Inc	82.05 %
Lensar Inc	75.31 %
Ironwood Pharmaceuticals inc	70.54 %
Oramed Pharmaceuticals Inc	68.90 %
Indivior Pharmaceuticals Inc	68.79 %
Rallybio Corporation	68.28 %
Fortress Biotech Inc	68.27 %
Earth Science Tech Inc	64.38 %
Meiragtx Holdings Plc	55.83 %
Elite Pharmaceuticals Inc	53.48 %
Idexx Laboratories Inc	51.80 %
Aurinia Pharmaceuticals Inc	50.35 %
Qhslab Inc	48.94 %
Q32 Bio Inc	47.43 %
Vaxart Inc	46.17 %
Liquidia Corporation	42.09 %

Date modified: 2026-09-03T11:57:59+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.